IMS 2022 | Single-cell RNA sequencing of BM and PB samples from patients with high-risk smoldering myeloma
Romanos Sklavenitis-Pistofidis, MD , Dana-Farber Cancer Institute, Boston, MA, shares the results of a study that performed single-cell RNA sequencing (scRNA-seq) of bone marrow (BM) and peripheral blood (PB) samples from patients with high-risk smoldering myeloma treated with elotuzumab, lenalidomide, and dexamethasone. Overall, the study found significant changes in the immune cell composition of patients with smoldering myeloma in comparison to healthy donors, and showed that the similarity in immune cell composition between patients with smoldering myeloma and healthy donors was prognostically relevant. In addition, the study reported that patients who achieved post-therapy immune normalization had a longer progression-free survival (PFS) and demonstrated that PB samples are able to reflect the immune dysregulation present in the BM. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
